NZ532635A
(en)
|
2001-11-13 |
2007-05-31 |
Univ Pennsylvania |
A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
DK2292780T3
(en)
|
2003-09-30 |
2017-12-04 |
Univ Pennsylvania |
Clades and sequences of adeno-associated virus (AAV), vectors containing them, and uses thereof
|
WO2006110689A2
(en)
*
|
2005-04-07 |
2006-10-19 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an aav vector
|
CN101528916B
(en)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
Scalable production method for AAV
|
EP2037892B1
(en)
*
|
2006-06-19 |
2015-03-18 |
Asklepios Biopharmaceutical, Inc. |
Modified factor viii and factor ix genes and vectors for gene therapy
|
EP3492596A1
(en)
*
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
GB2472964B
(en)
|
2008-05-20 |
2013-04-24 |
Eos Neuroscience Inc |
Vectors for delivery of light-sensitive proteins and methods of use
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
TR201906398T4
(en)
*
|
2009-04-30 |
2019-05-21 |
Univ Pennsylvania |
Compositions for targeting conductive airway cells containing gland-associated virus structures.
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2011038187A1
(en)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
SG183929A1
(en)
|
2010-03-29 |
2012-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
WO2011133901A2
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
WO2012007458A1
(en)
|
2010-07-12 |
2012-01-19 |
Universidad Autónoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
CN103189507A
(en)
*
|
2010-10-27 |
2013-07-03 |
学校法人自治医科大学 |
Adeno-associated virus virions for transferring genes into neural cells
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
EP2699680B1
(en)
|
2011-04-21 |
2017-12-27 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
JP6072772B2
(en)
|
2011-04-22 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Adeno-associated virus virions with mutant capsids and methods of use thereof
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
BR112014020325A2
(en)
*
|
2012-02-17 |
2017-08-08 |
Childrens Hospital Philadelphia |
aav vector compositions and methods for gene transfer to cells, organs and tissues
|
DK2839014T3
(en)
|
2012-04-18 |
2021-03-08 |
Childrens Hospital Philadelphia |
COMPOSITION AND METHODS FOR HIGH-EFFICIENT TRANSFER USING AAV CAPSID VARIANTS
|
TWI775096B
(en)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
Treatment of amd using aav sflt-1
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
BR112015002168A2
(en)
|
2012-08-01 |
2017-11-07 |
Nationwide Childrens Hospital |
intrathecal release of recombinant adeno-associated virus 9
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
AU2013323270B2
(en)
*
|
2012-09-28 |
2017-09-28 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
MX2015012739A
(en)
|
2013-03-15 |
2016-02-19 |
Univ Pennsylvania |
Compositions and methods for treating mpsi.
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
CA2917018A1
(en)
*
|
2013-05-21 |
2014-12-04 |
University Of Florida Research Foundation, Inc. |
Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
|
WO2014194132A1
(en)
*
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
HUE047996T2
(en)
*
|
2013-07-22 |
2020-05-28 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
EP3049527A4
(en)
|
2013-09-26 |
2017-08-16 |
University of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
CN106029107A
(en)
*
|
2013-10-07 |
2016-10-12 |
基罗米克有限责任公司 |
Compositions and methods for treating cardiovascular diseases using disease-specific promoter
|
PL3459965T3
(en)
|
2013-10-11 |
2021-07-26 |
Massachusetts Eye & Ear Infirmary |
Methods of predicting ancestral virus sequences and uses thereof
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
US9890365B2
(en)
|
2014-03-09 |
2018-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
|
IL259321B2
(en)
|
2014-03-17 |
2023-10-01 |
Univ Washington |
Compositions and methods for enhanced gene expression in cone cells
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
BR112016024379A2
(en)
|
2014-04-25 |
2017-10-10 |
Univ Pennsylvania |
ldlr variants and their use in compositions to lower cholesterol levels
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
EP3137497B1
(en)
*
|
2014-05-02 |
2021-04-07 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
CA2947614C
(en)
|
2014-05-13 |
2023-10-03 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
CN107427557B
(en)
*
|
2014-08-13 |
2022-01-04 |
费城儿童医院 |
Improved expression modules for packaging and expressing variant factor VIII for treatment of hemophilia
|
EP3194430A1
(en)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
BR112017007737A2
(en)
|
2014-10-21 |
2018-01-30 |
Univ Massachusetts |
recombinant aav variants and uses thereof
|
CN107106689A
(en)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
AADC polynucleotides for treating Parkinson's
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
MX2017006216A
(en)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als).
|
CN114480440A
(en)
|
2014-11-21 |
2022-05-13 |
北卡罗来纳-查佩尔山大学 |
AAV vectors targeting the central nervous system
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
WO2016126857A1
(en)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
CN114480502A
(en)
|
2015-03-02 |
2022-05-13 |
阿德夫拉姆生物技术股份有限公司 |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
ES2836258T3
(en)
|
2015-03-10 |
2021-06-24 |
Univ Columbia |
Recombinant GLUT1 Adeno-Associated Viral Vector Constructs and Related Methods for Restoring GLUT1 Expression
|
JP6836999B2
(en)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
Adeno-associated virus mutants and how to use them
|
US10555994B2
(en)
*
|
2015-03-30 |
2020-02-11 |
Boehringer Ingelheim Animal Health USA Inc. |
PCV2 ORF2 carrier platform
|
WO2016176191A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
Methods of delivering an agent to the eye
|
EA201792500A1
(en)
|
2015-05-13 |
2018-04-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
AAV-MEDIATED EXPRESSION OF ANTIBODIES AGAINST FLU AND METHODS OF THEIR USE
|
EP3313991B1
(en)
|
2015-06-23 |
2024-07-17 |
The Children's Hospital of Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
DK3872085T5
(en)
*
|
2015-07-30 |
2024-08-12 |
Massachusetts Eye & Ear Infirmary |
STOCK VIRUS SEQUENCES AND USES THEREOF
|
US10166255B2
(en)
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
AU2016302335B2
(en)
|
2015-08-06 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
GLP-1 and use thereof in compositions for treating metabolic diseases
|
MX2018002339A
(en)
|
2015-08-25 |
2018-12-19 |
Univ Duke |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases.
|
AU2016315699B2
(en)
|
2015-08-31 |
2021-09-09 |
The Trustees Of The University Of Pennsylvania |
AAV-EPO for treating companion animals
|
IL296929A
(en)
|
2015-09-24 |
2022-12-01 |
Univ Pennsylvania |
Composition and method for treating complement-mediated disease
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
WO2017070476A2
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US11135313B2
(en)
|
2015-10-28 |
2021-10-05 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
IL303850A
(en)
|
2015-12-11 |
2023-08-01 |
Univ Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
ES2918998T3
(en)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Scalable purification method for AAVrh10
|
SG10201913266UA
(en)
|
2015-12-11 |
2020-02-27 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
US11241506B2
(en)
|
2015-12-14 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
CN109069668B
(en)
|
2015-12-14 |
2023-04-18 |
宾夕法尼亚州大学信托人 |
Gene therapy for eye diseases
|
EP3390429A4
(en)
*
|
2015-12-14 |
2019-07-17 |
The University of North Carolina at Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
JP7360241B2
(en)
|
2016-02-03 |
2023-10-12 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Gene therapy to treat mucopolysaccharidosis type I
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
EP3452104A1
(en)
|
2016-04-15 |
2019-03-13 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
JP7046828B2
(en)
|
2016-04-15 |
2022-04-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Composition for the treatment of exudative age-related macular degeneration
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
EP3443108A4
(en)
|
2016-04-15 |
2019-11-20 |
The Trustees of The University of Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
RU2725286C2
(en)
|
2016-05-13 |
2020-06-30 |
4Д Молекьюлар Терапьютикс Инк. |
Versions of adenoassociated virus capsids and methods of use thereof
|
KR102392236B1
(en)
|
2016-05-18 |
2022-05-03 |
보이저 테라퓨틱스, 인크. |
Regulatory Polynucleotides
|
SG11201809643UA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
RU2764919C2
(en)
|
2016-06-13 |
2022-01-24 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Optimized cln1 genes and expression cassettes, and their application
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
RU2764920C2
(en)
|
2016-07-08 |
2022-01-24 |
Зе Трастис Оф Зе Юниверсити Оф Пенсильвания |
Methods and compositions for the treatment of disorders and diseases related to rdh12
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
SG11201811603WA
(en)
*
|
2016-07-26 |
2019-02-27 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
CN114672516A
(en)
|
2016-07-29 |
2022-06-28 |
加利福尼亚大学董事会 |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
AU2017313917B2
(en)
|
2016-08-18 |
2023-12-21 |
The Regents Of The University Of California |
CRISPR-Cas genome engineering via a modular AAV delivery system
|
EP3831281A1
(en)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
EP3518985A4
(en)
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
KR20190075964A
(en)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
AAV capsid design
|
JP7181862B2
(en)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Tumor-infiltrating lymphocytes and methods of treatment
|
EP3528785A4
(en)
|
2016-10-19 |
2020-12-02 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
ES2931960T3
(en)
|
2016-12-01 |
2023-01-05 |
Inst Nat Sante Rech Med |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
CN110462037A
(en)
*
|
2017-01-30 |
2019-11-15 |
学校法人日本医科大学 |
The mutant of adeno-associated virus (AAV) capsid protein
|
KR20190118163A
(en)
|
2017-02-20 |
2019-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Gene therapy to treat familial hypercholesterolemia
|
AU2018224044B2
(en)
|
2017-02-21 |
2024-01-25 |
The Uab Research Foundation |
Modified AAV capsid proteins and uses thereof
|
SI3589730T1
(en)
|
2017-02-28 |
2024-04-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
JOP20190200A1
(en)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
Compositions useful in treatment of spinal muscular atrophy
|
SG10201913833PA
(en)
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
RU2019130004A
(en)
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
GENE THERAPY FOR EYE DISEASES
|
IL269892B2
(en)
|
2017-04-14 |
2024-04-01 |
Regenxbio Inc |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
EP3619308A4
(en)
|
2017-05-05 |
2021-01-27 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
CA3061652A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
SG10201912401QA
(en)
|
2017-05-11 |
2020-02-27 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinoses
|
CN108103082B
(en)
*
|
2017-05-11 |
2021-07-13 |
北京锦篮基因科技有限公司 |
Adeno-associated virus mediated LCAT gene expression vector and application thereof
|
US11793887B2
(en)
|
2017-05-31 |
2023-10-24 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
US11827898B2
(en)
|
2017-06-14 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(en)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
KR20240063170A
(en)
|
2017-07-06 |
2024-05-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
JP7229989B2
(en)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
Trajectory array guide system
|
KR20200044793A
(en)
|
2017-08-03 |
2020-04-29 |
보이저 테라퓨틱스, 인크. |
Compositions and methods for delivery of AAV
|
CA3073937A1
(en)
*
|
2017-08-25 |
2019-02-28 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
JP2020534788A
(en)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Adeno-associated virus capsid mutant and how to use it
|
BR112020005436B1
(en)
|
2017-09-20 |
2022-08-02 |
4D Molecular Therapeutics Inc |
ADENO-ASSOCIATED VIRUS VARIANT CAPSID PROTEIN, INFECTIOUS AAV VIRION (RAAV) VIRION, COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS AND USES OF RAAV VIRION OR PHARMACEUTICAL COMPOSITIONS
|
EP3684938A1
(en)
|
2017-09-22 |
2020-07-29 |
The Trustees of the University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
JP7502991B2
(en)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Treatment of amyotrophic lateral sclerosis (ALS)
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
MX2020003945A
(en)
|
2017-10-18 |
2020-11-09 |
Regenxbio Inc |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap.
|
MX2020003888A
(en)
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics.
|
PT3717636T
(en)
|
2017-11-27 |
2023-05-30 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
MX2020005673A
(en)
|
2017-11-30 |
2020-12-03 |
Univ Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib.
|
BR112020010735A2
(en)
|
2017-11-30 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
gene therapy for mucopolysaccharidosis iii a
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
US10806802B2
(en)
|
2018-01-18 |
2020-10-20 |
University Of Guelph |
Adeno-associated virus particle with mutated capsid and methods of use thereof
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
CN112041437A
(en)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
US20210123073A1
(en)
*
|
2018-02-27 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
EP3758724A4
(en)
*
|
2018-02-27 |
2022-07-06 |
The Trustees of The University of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
JP2021519612A
(en)
*
|
2018-03-29 |
2021-08-12 |
アスクレピオス バイオファーマシューティカル, インコーポレイテッド |
Liver-tropic recombinant AAV6 vector to avoid neutralization
|
WO2019195701A1
(en)
|
2018-04-05 |
2019-10-10 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation
|
MA51353B1
(en)
|
2018-04-05 |
2022-09-30 |
Univ Sorbonne |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced hepatic tropism
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
CA3098566A1
(en)
|
2018-04-29 |
2019-11-07 |
Zhuchun WU |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
SG11202009914SA
(en)
|
2018-05-08 |
2020-11-27 |
Rutgers The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
TW202005978A
(en)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
Novel liver targeting adeno-associated viral vectors
|
MA52631A
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
WO2019241535A2
(en)
|
2018-06-14 |
2019-12-19 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant aav production
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
JP7413629B2
(en)
|
2018-07-17 |
2024-01-16 |
ヘリックスミス カンパニー, リミテッド |
Treatment of neurological diseases using DNA constructs expressing IGF-1 variants
|
CA3107462A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
EP3829718A4
(en)
*
|
2018-07-31 |
2022-06-22 |
Cornell University |
Gene therapy methods to control organ function
|
JP2021533757A
(en)
|
2018-08-10 |
2021-12-09 |
リジェネクスバイオ インコーポレイテッド |
A scalable method for recombinant AAV generation
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
US20210317478A1
(en)
*
|
2018-08-21 |
2021-10-14 |
Massachusetts Eye And Ear Infirmary |
Compositions and methods for modulating transduction efficiency of adeno-associated viruses
|
JP7450945B2
(en)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス, インコーポレイテッド |
Cardiac cell reprogramming using myocardin and ASCL1
|
CN113383010A
(en)
|
2018-09-28 |
2021-09-10 |
沃雅戈治疗公司 |
Ataxin expression constructs with engineered promoters and methods of use thereof
|
JP7534290B2
(en)
|
2018-10-01 |
2024-08-14 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Compositions useful for treating gm1 gangliosidosis
|
EP3861113A1
(en)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
SG11202103425YA
(en)
|
2018-10-05 |
2021-05-28 |
Voyager Therapeutics Inc |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
JP2022514112A
(en)
|
2018-10-15 |
2022-02-09 |
リジェネクスバイオ インコーポレイテッド |
Replication-deficient viral vectors and methods for measuring viral infectivity
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
DK3906066T5
(en)
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF WILSON'S DISEASE
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
CN113347962A
(en)
*
|
2019-01-23 |
2021-09-03 |
佛罗里达大学研究基金会有限公司 |
High efficiency transduction and lateral spread of novel AAV viruses in the retina enhanced by rational design
|
US20230193315A1
(en)
|
2019-01-31 |
2023-06-22 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
EP3927381A1
(en)
|
2019-02-22 |
2021-12-29 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
CN113677801A
(en)
|
2019-02-25 |
2021-11-19 |
诺华股份有限公司 |
Compositions and methods for treating BIETTI crystal dystrophy
|
JP2022520875A
(en)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Compositions and Methods for Treating Bietti Crystallin Retinopathy
|
MX2021010266A
(en)
|
2019-02-26 |
2021-09-23 |
Univ Pennsylvania |
Compositions useful in treatment of krabbe disease.
|
AU2020253462A1
(en)
|
2019-04-03 |
2021-10-28 |
Regenxbio Inc. |
Gene therapy for eye pathologies
|
TW202102526A
(en)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
Recombinant adeno-associated viruses and uses thereof
|
HUE064411T2
(en)
|
2019-04-11 |
2024-03-28 |
Regenxbio Inc |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
US20220143115A1
(en)
|
2019-04-19 |
2022-05-12 |
Regenxbio Inc. |
Adeno-Associated Virus Vector Formulations and Methods
|
CA3136872A1
(en)
*
|
2019-04-23 |
2020-10-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New adeno-associated virus (aav) variants and uses thereof for gene therapy
|
TW202106708A
(en)
|
2019-04-24 |
2021-02-16 |
美商銳進科斯生物股份有限公司 |
Fully-human post-translationally modified antibody therapeutics
|
JP2022530845A
(en)
*
|
2019-04-27 |
2022-07-04 |
オクジェン アイエヌシー. |
ADENO-associated virus-linked viral vector-mediated gene therapy for eye disease
|
MX2021013267A
(en)
*
|
2019-04-29 |
2021-11-17 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same.
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
KR20220081971A
(en)
*
|
2019-07-15 |
2022-06-16 |
메이라지티엑스 유케이 Ii 리미티드 |
Modified AAV Capsid Protein for Treatment of Arthritic Diseases
|
WO2021021661A1
(en)
|
2019-07-26 |
2021-02-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
AU2020336314A1
(en)
|
2019-08-26 |
2022-04-07 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-VEGF Fab
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
JP2022547305A
(en)
|
2019-09-13 |
2022-11-11 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
AAV compatible laminin-linker polymeric protein
|
JP2022550435A
(en)
|
2019-10-04 |
2022-12-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Methods for improved therapeutic use of recombinant AAV
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
CN118221785A
(en)
*
|
2019-10-16 |
2024-06-21 |
上海药明康德新药开发有限公司 |
Novel AAV variants
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
KR20220107222A
(en)
|
2019-11-28 |
2022-08-02 |
리젠엑스바이오 인크. |
Microdystrophin gene therapy constructs and uses thereof
|
US11981912B2
(en)
|
2019-12-10 |
2024-05-14 |
Takeda Pharma ceutical Company Limited |
Adeno associated virus vectors for the treatment of hunter disease
|
EP4072572A4
(en)
*
|
2019-12-10 |
2024-01-03 |
Homology Medicines, Inc. |
Adeno-associated virus compositions and methods of use thereof
|
TW202140791A
(en)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
Methods of treating phenylketonuria
|
US20230059395A1
(en)
|
2020-01-22 |
2023-02-23 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
TW202142695A
(en)
|
2020-01-29 |
2021-11-16 |
美商銳進科斯生物股份有限公司 |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
MX2022009462A
(en)
|
2020-02-02 |
2022-11-10 |
Univ Pennsylvania |
Compositions useful for treating gm1 gangliosidosis.
|
US20230054144A1
(en)
|
2020-02-14 |
2023-02-23 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
BR112022016965A2
(en)
*
|
2020-02-25 |
2022-12-06 |
Childrens Medical Res Institute |
ADENO-ASSOCIATED VIRUS POLYPEPTIDES AND CAPSID VECTORS
|
EP4121544A1
(en)
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
KR20220160069A
(en)
|
2020-03-27 |
2022-12-05 |
유씨비 바이오파마 에스알엘 |
autonomous knob domain peptide
|
EP4127189A1
(en)
|
2020-03-31 |
2023-02-08 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
WO2021211629A2
(en)
*
|
2020-04-13 |
2021-10-21 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using a vaccine against coronavirus
|
CN116249712A
(en)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
TAU binding compounds
|
CA3177924A1
(en)
|
2020-05-12 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
KR20230010670A
(en)
|
2020-05-12 |
2023-01-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Compositions for DRG-specific reduction of transgene expression
|
CN116801911A
(en)
|
2020-05-13 |
2023-09-22 |
阿库斯股份有限公司 |
Compositions and methods for treating SLC26A 4-associated hearing loss
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
CA3173450A1
(en)
|
2020-05-26 |
2021-12-02 |
Francois Vigneault |
High throughput engineering of functional aav capsids
|
TW202208632A
(en)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CN115968302A
(en)
|
2020-06-17 |
2023-04-14 |
宾夕法尼亚州大学信托人 |
Compositions and methods for treating gene therapy patients
|
AU2021305665A1
(en)
|
2020-07-10 |
2023-02-23 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating epilepsy
|
AU2021309645A1
(en)
|
2020-07-13 |
2023-02-09 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treatment of charcot-marie-tooth disease
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
KR20230093241A
(en)
|
2020-07-27 |
2023-06-27 |
보이저 테라퓨틱스, 인크. |
Compositions and methods for the treatment of neurological disorders associated with glucosylceramides beta deficiency
|
CN115927398A
(en)
*
|
2020-07-29 |
2023-04-07 |
舒泰神(北京)生物制药股份有限公司 |
Acquisition and application of novel liver-targeted adeno-associated viruses
|
KR20230054840A
(en)
|
2020-07-30 |
2023-04-25 |
셰이프 테라퓨틱스 인코포레이티드 |
Stabilized cell lines for directed production of rAAV virions
|
JP2023543125A
(en)
|
2020-08-24 |
2023-10-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Viral vectors encoding GLP-1 receptor agonist fusions and their use in the treatment of metabolic diseases
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
EP4225926A1
(en)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
MX2023004035A
(en)
|
2020-10-07 |
2023-07-05 |
Regenxbio Inc |
Formulations for suprachoroidal administration such as high viscosity formulations.
|
AU2021358964A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
CA3194861A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
WO2022076711A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
TW202229560A
(en)
|
2020-10-09 |
2022-08-01 |
賓州大學委員會 |
Compositions and methods for treatment of fabry disease
|
US20230383313A1
(en)
|
2020-10-18 |
2023-11-30 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
AU2021392642A1
(en)
|
2020-12-01 |
2023-06-22 |
The Trustees Of The University Of Pennsylvania |
Compositions and uses thereof for treatment of angelman syndrome
|
IL303236A
(en)
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
KR20230117179A
(en)
|
2020-12-01 |
2023-08-07 |
아카우오스, 인크. |
Anti-VEGF antibody constructs and related methods for treating symptoms associated with acoustic schwannoma
|
EP4263841A1
(en)
|
2020-12-16 |
2023-10-25 |
REGENXBIO Inc. |
Method of producing a recombinant adeno-associated virus particle
|
MX2023007800A
(en)
|
2020-12-29 |
2023-07-11 |
Akouos Inc |
Compositions and methods for treating clrn1-associated hearing loss and/or vision loss.
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
US20240084329A1
(en)
|
2021-01-21 |
2024-03-14 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
US11926842B2
(en)
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
EP4291249A2
(en)
|
2021-02-10 |
2023-12-20 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
TW202302855A
(en)
|
2021-02-26 |
2023-01-16 |
日商武田藥品工業股份有限公司 |
Composition and methods for the treatment of fabry disease
|
US20240191258A1
(en)
|
2021-04-12 |
2024-06-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating spinal and bulbar muscular atrophy (sbma)
|
MX2023012513A
(en)
|
2021-04-23 |
2023-12-15 |
Univ Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same.
|
WO2022226296A2
(en)
|
2021-04-23 |
2022-10-27 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
WO2022232141A1
(en)
|
2021-04-26 |
2022-11-03 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
WO2022235614A2
(en)
|
2021-05-04 |
2022-11-10 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
WO2022272297A1
(en)
|
2021-06-25 |
2022-12-29 |
Oxford Biomedica Solutions Llc |
Adeno-associated virus packaging systems
|
KR20240051112A
(en)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
Engineered Natural Killer (NK) Cells and Related Methods
|
AU2022313258A1
(en)
|
2021-07-19 |
2024-02-08 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
JP2024531138A
(en)
|
2021-08-11 |
2024-08-29 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Compositions and methods for treating muscular dystrophies
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
JP2024531234A
(en)
|
2021-08-11 |
2024-08-29 |
サナ バイオテクノロジー,インコーポレイテッド |
Genetically modified primary cells for allogeneic cell therapy
|
US20230090654A1
(en)
|
2021-08-24 |
2023-03-23 |
Homology Medicines, Inc. |
Adeno-associated virus formulations
|
AU2022335593A1
(en)
*
|
2021-08-25 |
2024-03-14 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease
|
WO2023034880A2
(en)
|
2021-08-31 |
2023-03-09 |
Scout Bio, Inc. |
Antigen-binding molecules and uses thereof
|
AU2022356427A1
(en)
|
2021-09-30 |
2024-05-09 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
CN118202060A
(en)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
Compositions and methods for recombinant AAV production
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023072181A1
(en)
*
|
2021-10-28 |
2023-05-04 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Adeno-associated virus capsid
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023077086A1
(en)
|
2021-10-29 |
2023-05-04 |
Homology Medicines, Inc. |
Methods and compositions for the purification of adeno-associated virus
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
WO2023093905A1
(en)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
WO2023102079A1
(en)
|
2021-12-01 |
2023-06-08 |
Shape Therapeutics Inc. |
Functional aav capsids for systemic administration
|
WO2023102078A2
(en)
|
2021-12-01 |
2023-06-08 |
Shape Therapeutics Inc. |
Functional aav capsids for intravitreal administration
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
JPWO2023106256A1
(en)
*
|
2021-12-06 |
2023-06-15 |
|
|
WO2023114897A2
(en)
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
AU2023211652A1
(en)
|
2022-01-25 |
2024-08-08 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
TW202342525A
(en)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
TW202342740A
(en)
|
2022-03-07 |
2023-11-01 |
美商奧崔基尼克斯製藥公司 |
Modified batch aav production systems and methods
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(en)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
Modified muscle-specific promoters
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
TW202404651A
(en)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
TW202345913A
(en)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
Formulations for suprachoroidal administration such as gel formulations
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
AR129215A1
(en)
|
2022-05-03 |
2024-07-31 |
Regenxbio Inc |
ANTI-COMPLEMENT ANTIBODIES AND VECTORIZED COMPLEMENT AGENTS AND THEIR ADMINISTRATION
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
CN115960177B
(en)
*
|
2022-10-09 |
2023-07-07 |
广州派真生物技术有限公司 |
Adeno-associated virus mutant and application thereof
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
CN116789739B
(en)
*
|
2022-12-08 |
2024-01-26 |
广州派真生物技术有限公司 |
Adeno-associated virus mutant and application thereof
|
WO2024130067A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
WO2024134525A1
(en)
|
2022-12-22 |
2024-06-27 |
Fondazione Telethon Ets |
Lsd1 inhibitor and prmt6 inhibitor for use in the treatment of a disease associated with gain-of-function of androgen receptor (ar) and/or with overexpression of an ar coactivator
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
CN118460614A
(en)
*
|
2024-07-05 |
2024-08-09 |
凌意(杭州)生物科技有限公司 |
Expression frame of adeno-associated virus Cap protein
|